Glitazones should be avoided in patients with overt heart failure; 5, The novel incretin mimetic drugs and DPP-4 inhibitors – while usually inadequate as monotherapy – appear to be satisfactory adjuvant drugs due to the lack of known undesirable cardiovascular effects; 6. The gene discussed is DPP4; the disease is heart failure.